While C4 Therapeutics Inc has overperformed by 1.39%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CCCC fell by -20.51%, with highs and lows ranging from $11.88 to $3.16, whereas the simple moving average fell by -28.59% in the last 200 days.
On November 18, 2024, Stephens started tracking C4 Therapeutics Inc (NASDAQ: CCCC) recommending Equal-Weight. A report published by JP Morgan on January 29, 2024, Upgraded its rating to ‘Neutral’ for CCCC. Stifel also Upgraded CCCC shares as ‘Buy’, setting a target price of $12 on the company’s shares in a report dated December 13, 2023. Credit Suisse February 24, 2023d the rating to Neutral on February 24, 2023, and set its price target from $12 to $10. JP Morgan February 24, 2023d its ‘Neutral’ rating to ‘Underweight’ for CCCC, as published in its report on February 24, 2023. JP Morgan’s report from November 04, 2022 suggests a price prediction of $15 for CCCC shares, giving the stock a ‘Neutral’ rating. Morgan Stanley also rated the stock as ‘Underweight’.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Analysis of C4 Therapeutics Inc (CCCC)
Further, the quarter-over-quarter increase in sales is 38.75%, showing a positive trend in the upcoming months.
C4 Therapeutics Inc’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of -46.00% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 6.31, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and CCCC has an average volume of 1.14M. On a monthly basis, the volatility of the stock is set at 10.23%, whereas on a weekly basis, it is put at 14.53%, with a loss of -0.90% over the past seven days. Furthermore, long-term investors anticipate a median target price of $14.50, showing growth from the present price of $4.38, which can serve as yet another indication of whether CCCC is worth investing in or should be passed over.
How Do You Analyze C4 Therapeutics Inc Shares?
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 19.37%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 83.28% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
CCCC shares are owned by institutional investors to the tune of 83.28% at present.
